key: cord-1055852-s9z26fie
authors: Domínguez‐Gil, Beatriz; Coll, Elisabeth; Fernández‐Ruiz, Mario; Corral, Esther; del Río, Francisco; Zaragoza, Rafael; Rubio, Juan J.; Hernández, Domingo
title: COVID‐19 in Spain: Transplantation in the midst of the pandemic
date: 2020-05-27
journal: Am J Transplant
DOI: 10.1111/ajt.15983
sha: 02f5a4d126cb36ebb5bece67a71195e375145cb1
doc_id: 1055852
cord_uid: s9z26fie

Spain has been one of the most affected countries by the COVID‐19 outbreak. As of April 28, 2020, the number of confirmed cases is 210 773, including 102 548 patients recovered, more than 10 300 admitted to the ICU, and 23 822 deaths, with a global case fatality rate of 11.3%. From the perspective of donation and transplantation, the Spanish system first focused on safety issues, providing recommendations for donor evaluation and testing, and to rule out SARS‐CoV‐2 infection in potential recipients prior to transplantation. Since the country entered into an epidemiological scenario of sustained community transmission and saturation of intensive care, developing donation and transplantation procedures has become highly complex. Since the national state of alarm was declared in Spain on March 13, 2020, the mean number of donors has declined from 7.2 to 1.2 per day, and the mean number of transplants from 16.1 to 2.1 per day. Increased mortality on the waiting list may become a collateral damage of this terrible pandemic.

At the beginning of December 2019, clusters of patients diagnosed of pneumonia of unknown origin were reported in the city of Wuhan, province of Hubei (China). 1 The pathogen was identified as a new betacoronavirus, named severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), with a high phylogenetic similarity with the SARS-CoV virus, first identified in the Chinese province of Guangdong in 2002. 2 By international consensus, the infection caused by SARS-CoV-2 is named Coronavirus Disease 2019 . In the last weeks, the number of cases of COVID-19 has increased to more than 3 million reported by 185 countries throughout the world. 3 On March 11, 2020, the World Health Organization officially declared the COVID-19 outbreak a pandemic. 4 Spain has been one of the most affected countries in the world in terms of absolute number of diagnosed cases. On March 13, 2020 (legally effective on March 15), the Government declared a national state of alarm, with regulations targeted to facilitate diagnosis, ensure appropriate treatment of cases, and reduce the spread of COVID-19, including measures of national lockdown, confinement of the population, and restricted mobility. 5 As of April 28, 2020, the number of confirmed cases in Spain is 210,773, including 105 548 patients recovered, more than 10 300 admitted to the intensive care unit (ICU), and 23 822 deaths, with a global case fatality rate of 11.3%. 6 The accumulated incidence of COVID-19 in the last 14 days is 81.28 per 100 000 inhabitants, with marked variations across regions (from 10.63 to 182.78). The country as a whole is currently considered to be in epidemiological scenarios 3 (sustained community transmission) and 4 (intensive care capacity saturated and health-care system overwhelmed), as described by the European Centre for Disease Control and Prevention. 7 From the perspective of donation and transplantation, the Spanish system first focused on the possibility of donor-derived COVID-19. In January 2020, the Organización Nacional *Donation will be considered on a case-by-case basis in cured cases of COVID-19 after a minimum of 21 d following resolution of symptoms and completion of therapy. A cured case is defined as follows: Patient with confirmed COVID-19 (or highly suspicious) who was hospitalized: 21 d after the complete resolution of symptoms AND two negative SARS-CoV-2 RT-PCR in respiratory tract samples obtained >24 h apart. Patient with confirmed COVID-19 who was isolated at home: 21 d after the complete resolution of symptoms AND 2 negative SARS-CoV-2 RT-PCR in respiratory tract samples obtained >24 h apart. Patient with probable COVID-19 (ie, with no microbiological confirmation), who was isolated at home with suggestive symptoms and/or exposure to a confirmed case of COVID-19: if symptoms continue, donation will not proceed; if contact has occurred within the previous 21 d, screening for SARS-CoV-2 will be performed; if contact has occurred beyond the previous 21 d, donation will be considered as for any other potential donor not proceed if the result is positive or inconclusive. Testing is also extended to all potential donors with no epidemiological risk if donation of lung and/or small bowel is considered, or if they present symptoms compatible with COVID-19. Since the entire country currently represents an affected area, universal screening is now the rule as derived from applying the above described recommendations. Also, bearing in mind the number of cured patients in the country, organ donation is considered after a minimum period of 21 days following the resolution of symptoms and the completion of treatment, provided that viral clearance has been demonstrated and a cautious case by case risk/benefit assessment has been performed. In live donation, the recommendation is to defer surgery for 21 days in donors with epidemiological risk. Currently, all live donation procedures are being postponed. The matching runs of the national kidney paired exchange program have been deferred as well.

With regard to the samples for testing, our recommendation is to use samples from the upper (nasopharyngeal and oropharyngeal swab) or the lower respiratory tract (preferentially, bronchoalveolar lavage) taken within 24 hours prior to organ recovery. A brochoalveolar lavage sample is always preferred, and required in case of lung or small bowel donation. The deferral period set of 21 days differs from that recommended by others. 7 Although the incubation period of COVID-19 has been consistently established within the range of 2-14 days, we wanted to rule out potential outliers.

In practice, applying the previously mentioned scheme has proved challenging due to the limited access to RT-PCR testing in some hospitals and the time required to have results available. Laboratories 13 It is also likely that the period of viral clearing is longer than in nontransplanted patients, with the corresponding impact on the control of disease transmission. 14, 15 Proceeding with a transplant in a patient who may be infected can, not only place that patient at high risk following immunosuppression, but turn them into "super-shedders" of the virus particularly among health-care workers. 10 This has prompted us to issue the recommendation of testing recipients upon their arrival to the hospital prior to transplantation-which will not proceed should the patient exhibit symptoms compatible with COVID-19 or test positive for SARS-CoV-2.

Safety issues have however not been the most important barrier in our field, but the saturation of the health-care system and of the ICU capacity, that has prompted the Spanish Society of Intensive and Critical Care, and Coronary Units (SEMICYUC) to develop a national contingency plan. 16 As the number of cases started raising in Spain, and particularly since the state of alarm was declared, ICU resources have been focused on the treatment of severe cases of COVID-19. Mortality on the waiting list may become a collateral damage of this terrible pandemic.

Every evening, at 20 hours, Spain breaks out in a big applause from windows and balconies in acknowledgment of health-care professionals who are combating COVID-19 at the frontline in hospitals and other facilities. With these lines, the authors wish to join that unique gesture of recognition that also includes all members of the Spanish donor coordination and transplant teams.

The authors have no conflict of interest to disclose as described by

the American Journal of Transplantation.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Beatriz Domínguez-Gil https://orcid.org/0000-0002-5695-8993

Mario Fernández-Ruiz https://orcid.org/0000-0002-0315-8001

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A novel coronavirus from patients with pneumonia in China

WHO Director-General's opening remarks at the media briefing on COVID

Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19

Calidad e Innovación, Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización nº 74 (13 de Abril de 2020)

COVID-19) pandemic: increased transmission in the EU/EEA and the UK -sixth update

infes p/Recom endac iones ParaP rofes ional es/Spani sh%20Rec ommen datio ns%20on%20Org an%20Don ation %20and %20Tra nspla ntati on%20COV ID-19%20ONT.pdf. Accessed

A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection

Coronavirus disease 2019: implications of emerging infections for transplantation

Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening

MERS CoV infection in two renal transplant recipients: case report

COVID-19 in solid organ transplant recipients: a single-center case series from Spain

Prolonged shedding of human coronavirus in hematopoietic cell transplant recipients: risk factors and viral genome evolution

Atypical presentations of MERS-CoV infection in immunocompromised hosts

Plan de contingencia para los servicios de medicina intensiva frente a la pandemia COVID-19

Coronavirus: 25.000 sanitarios infectados en España, 5.600 más en 6 días

Summary of Spanish recommendations on intensive care to facilitate organ donation

Uncontrolled donation after circulatory death: a unique opportunity

COVID-19 in Spain: Transplantation in the midst of the pandemic